Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP) Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014
Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015
Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015
Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016
Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016
Pulmonary alveolar proteinosis: A case report Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms Year: 2013
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016
Pulmonary thromboembolism (PE) in patients with interstitial lung diseases (ILD) Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias) Source: ERS Course 2016 Year: 2016
Rare interstitial lung diseases (LAM, LHC, alveolar proteinosis, eosinophilic pneumonias) Source: ERS Courses: Interstitial Lung Diseases Year: 2019
Surveillance of whole lung lavage for autoimmune pulmonary alveolar proteinosis in Japan Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013
Pulmonary alveolar proteinosis in a cat Source: International Congress 2015 – Interstitial lung diseases I Year: 2015
ILD-India registry: Idiopathic pulmonary fibrosis (IPF) and connective tissue disease (CTD) associated interstitial lung disease (CTD-ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013
Difficulties of diagnosis of pulmonary embolism (PE) in patients with lymphangioleiomyomatosis (LAM) Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013